Obesity and hormonal contraception: Safety and efficacy

Seminars in Reproductive Medicine

Volumn 30, Issue 6, 2012, Pages 479-485

  Edelman, Alison B ^a   Jensen, Jeffrey T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

body mass index; efficacy; obesity; safety; unplanned pregnancy; venous thromboembolism

Indexed keywords

CONTRACEPTIVE AGENT; ESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; ULIPRISTAL;

ARTERY THROMBOSIS; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CONTRACEPTION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INCIDENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; OBESITY; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; PREGNANCY; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; OBESITY; PREGNANCY; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84867536369     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0032-1328876     Document Type: Article

References (68)

1. Overweight and Obesity. U.S. Obesity trends (1985-2010). 2010: Available at: http://www.cdc.gov/obesity/data/trends.html. Accessed February 20, 2012
2. Boney C. M., Verma A., Tucker R., Vohr B. R. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics: 2005; 115 3 e290 e296 (Pubitemid 43373011)
3. Catalano P. M., Ehrenberg H. M. The short- and long-term implications of maternal obesity on the mother and her offspring. BJOG: 2006; 113 10 1126 1133 (Pubitemid 44401205)
4. Whitaker R. C. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics: 2004; 114 1 e29 e36
5. Marshall N. E., Spong C. Y. Obesity, pregnancy complications and birth outcomes. Semin Reprod Med: 2012; 30 6 463 469
6. Phelan S. Pregnancy: a "teachable momento" for weight control and obesity prevention. Am J Obstet Gynecol: 2010; 202 2 135, e1-e8
7. Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep: 2010; 59 RR-4 1 86
8. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol: 1998; 179 3 Pt 2 S62 S67 (Pubitemid 28447224)
9. Lidegaard O., Edström B., Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception: 1998; 57 5 291 301
10. Control CFD. Medical eligibility criteria for contraceptive use. Morb Mortal Wkly Rep (MMWR) CDC: 2010
11. Heinemann L. A., Dinger J. C. Range of published estimates of venous thromboembolism incidence in young women. Contraception: 2007; 75 5 328 336 (Pubitemid 46551070)
12. Liu S., Rouleau J., Joseph K. S., et al. Maternal Health Study Group of the Canadian Perinatal Surveillance System. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can: 2009; 31 7 611 620
13. Heit J. A. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis: 2006; 21 1 23 29 (Pubitemid 43231124)
14. Farmer R. D., Lawrenson R. A., Todd J. C., Williams T. J., MacRae K. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database. Hum Reprod Update: 1999; 5 6 688 706 (Pubitemid 30034892)
15. Dinger J. C., Heinemann L. A., Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception: 2007; 75 5 344 354 (Pubitemid 46551071)
16. Seeger J. D., Loughlin J., Eng P. M., Clifford C. R., Cutone J., Walker A. M. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol: 2007; 110 3 587 593 (Pubitemid 47359582)
17. Pomp E. R., le Cessie S., Rosendaal F. R., Doggen C. J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol: 2007; 139 2 289 296 (Pubitemid 47493087)
18. Nightingale A. L., Lawrenson R. A., Simpson E. L., Williams T. J., MacRae K. D., Farmer R. D. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care: 2000; 5 4 265 274 (Pubitemid 32165465)
19. Bonny A. E., Secic M., Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol: 2011; 117 4 793 797
20. Nilsson C. G., Lähteenmäki P., Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception: 1980; 21 3 225 233 (Pubitemid 10110387)
21. Shapiro S., Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care: 2010; 36 1 33 38
22. Heinemann L. A., Dinger J. C., Assmann A., Minh T. D. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare.o" Contraception: 2010; 81 5 401 407
23. Dinger J., Assmann A., Möhner S., Minh T. D. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care: 2010; 36 3 123 129
24. Johnson J. V., Lowell J., Badger G. J., Rosing J., Tchaikovski S., Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol: 2008; 111 2 Pt 1 278 284 (Pubitemid 351653416)
25. van den Heuvel M. W., van Bragt A. J., Alnabawy A. K., Kaptein M. C. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception: 2005; 72 3 168 174 (Pubitemid 41133355)
26. Edelman A. B., Cherala G., Stanczyk F. Z. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception: 2010; 82 4 314 323
27. Jensen J. T., Burke A. E., Barnhart K. T., Tillotson C., Messerle-Forbes M., Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception: 2008; 78 6 451 458
28. Grow D. R. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am: 2002; 29 3 425 436
29. Goebelsmann U., Mashchak C. A., Mishell D. R. Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol: 1985; 151 7 868 877 (Pubitemid 15237723)
30. Klipping C., Duijkers I., Parke S., Mellinger U., Serrani M., Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D: 2011; 11 2 159 170
31. Suissa S., Blais L., Spitzer W. O., Cusson J., Lewis M., Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception: 1997; 56 3 141 146 (Pubitemid 27450823)
32. Lawrenson R., Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference? Contraception: 2000; 62 2, Suppl 21S 28S; discussion 37S-38S
33. Kongsayreepong R., Chutivongse S., George P., et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception: 1993; 47 2 177 191
34. Godsland I. F., Crook D., Simpson R., et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med: 1990; 323 20 1375 1381
35. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud: 1995; 40 02 98 104
36. Dilbaz B., Ozdegirmenci O., Caliskan E., Dilbaz S., Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception: 2010; 81 6 510 514
37. Kayikcioglu F., Gunes M., Ozdegirmenci O., Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception: 2006; 73 5 528 531
38. Kahn H. S., Curtis K. M., Marchbanks P. A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care: 2003; 26 1 216 225 (Pubitemid 36929020)
39. Clarkson T. B., Shively C. A., Morgan T. M., Koritnik D. R., Adams M. R., Kaplan J. R. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol: 1990; 75 2 217 222 (Pubitemid 20062237)
40. Adams M. R., Clarkson T. B., Shively C. A., Parks J. S., Kaplan J. R. Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol: 1990; 163 4 Pt 2 1388 1393 (Pubitemid 20369745)
41. Picardo C. M., Nichols M., Edelman A., Jensen J. T. Women's knowledge and sources of information on the risks and benefits of oral contraception. J Am Med Womens Assoc: 2003; 58 2 112 116
42. Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception: 1998; 58 6 345 349 (Pubitemid 29095943)
43. Linné Y., Dye L., Barkeling B., Rössner S. Weight development over time in parous womenthe SPAWN study15 years follow-up. Int J Obes Relat Metab Disord: 2003; 27 12 1516 1522 (Pubitemid 38019165)
44. Blundell J. E., Stubbs R. J., Golding C., et al. Resistance and susceptibility to weight gain: individual variability in response to a high-fat diet. Physiol Behav: 2005; 86 5 614 622 (Pubitemid 41728979)
45. Gallo M. F., Grimes D. A., Schulz K. F., Helmerhorst F. M. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol: 2004; 103 2 359 373
46. Gallo M. F., Lopez L. M., Grimes D. A., Schulz K. F., Helmerhorst F. M. Combination contraceptives: effects on weight. Cochrane Database Syst Rev: 2008; 4 CD003987
47. Lopez L. M., Edelman A., Chen-Mok M., Trussell J., Helmerhorst F. M. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev: 2011; 4 CD008815
48. Andersson K., Odlind V., Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception: 1994; 49 1 56 72 (Pubitemid 24077388)
49. Sivin I., el Mahgoub S., McCarthy T., et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception: 1990; 42 4 361 378 (Pubitemid 20312978)
50. Roepke T. A. Oestrogen modulates hypothalamic control of energy homeostasis through multiple mechanisms. J Neuroendocrinol: 2009; 21 2 141 150
51. Mayes J. S., Watson G. H. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev: 2004; 5 4 197 216 (Pubitemid 39423001)
52. Edelman A., Jensen J. T., Bulechowsky M., Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod: 2011; 26 2 330 336
53. Society of Family Planning; Edelman A. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 2009. Contraception: 2009; 80 6 583 590
54. Westhoff C. L., Torgal A. T., Mayeda E. R., Shimoni N., Stanczyk F. Z., Pike M. C. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception: 2012; 85 5 465 469
55. Practice Committee of American Society for Reproductive Medicine. Obesity and reproduction: an educational bulletin. Fertil Steril: 2008; 90 5, Suppl S21 S29
56. Lewis R. A., Taylor D., Natavio M. F., Melamed A., Felix J., Mishell D. Jr. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception: 2010; 82 6 491 496
57. Brunner Huber L. R., Hogue C. J., Stein A. D., Drews C., Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol: 2006; 16 8 637 643 (Pubitemid 44093278)
58. Brunner Huber L. R., Toth J. L. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol: 2007; 166 11 1306 1311 (Pubitemid 350129421)
59. Dinger J., Minh T. D., Buttmann N., Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol: 2011; 117 1 33 40
60. Dinger J. C., Cronin M., Möhner S., Schellschmidt I., Minh T. D., Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol: 2009; 201 3 263, e1-e9
61. Holt V. L., Cushing-Haugen K. L., Daling J. R. Body weight and risk of oral contraceptive failure. Obstet Gynecol: 2002; 99 5 Pt 1 820 827 (Pubitemid 34442461)
62. Holt V. L., Scholes D., Wicklund K. G., Cushing-Haugen K. L., Daling J. R. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol: 2005; 105 1 46 52 (Pubitemid 40189910)
63. Kaneshiro B., Edelman A., Carlson N., Nichols M., Jensen J. The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception: 2008; 77 4 234 238
64. Segall-Gutierrez P., Taylor D., Liu X., Stanzcyk F., Azen S., Mishell D. R. Jr. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception: 2010; 81 6 487 495
65. Edelman A. B., Carlson N. E., Cherala G., et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception: 2009; 80 2 119 127
66. Mornar S., Chan L. N., Mistretta E., Neustadt A., Martins A., Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol: 2012; 207 2 110.e1 6
67. Westhoff C. L., Torgal A. H., Mayeda E. R., Pike M. C., Stanczyk F. Z. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception: 2010; 81 6 474 480
68. Glasier A., Cameron S. T., Blithe D., et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception: 2011; 84 4 363 367